Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05133596
Other study ID # 2021-006
Secondary ID 2021-A02419-32
Status Recruiting
Phase N/A
First received
Last updated
Start date June 20, 2022
Est. completion date November 9, 2024

Study information

Verified date March 2024
Source Institut Pasteur
Contact Pierre-Marie Lledo, Prof.
Phone 33 1 45688803
Email pierre-marie.lledo@pasteur.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The COVID-19 pandemic is a novel medical challenge, particularly because of the systemic nature of this disease. Indeed, COVID-19 affects several organs and systems at once. The brain is affected in several ways: direct infection of nerve cells by SARS-CoV-2, inflammation of the central nervous system, severe systemic inflammation damaging nerve cells, global cerebral ischaemia related to respiratory failure, thromboembolic events related to increased intravascular coagulation and severe psychological stress. As a result, COVID-19 sometimes manifests as neurological and neuropsychiatric symptoms such as dizziness, sleep disturbances, cognitive deficits, delirium, or severe depression. Sudden loss of smell is a common symptom associated with COVID-19 and SARS-CoV-2 infection of neurons in the olfactory system has been reported in both hamsters and humans. The vast majority of COVID-19 patients recover their olfactory function within a few weeks. However, a significant minority of infected individuals (1 in 5 cases) still suffers from olfactory disorders (anosmia, hyposmia and/or parosmia) several months after the primary infection. These olfactory disorders are frequently associated with depressive behaviour and cognitive complaints. In PET scans, it is even possible to correlate this cognitive dysfunction with hypometabolism of certain brain regions, including the olfactory gyrus. This project proposes, during one year, to evaluate and follow the evolution of the olfactory capacities of patients suffering from persistent smell disorder since one year (+/- 4 months) following COVID-19. The issue is to study the link between viral persistence in the olfactory sensory organ, chronic inflammation, and central damage to the olfactory system. The follow-up of the evolution of olfactory and neurocognitive capacities, in an integrative way by means of molecular, physiological and behavioural approaches, will inform us on the specificities of "COVID-long" and on the level of peripheral and/or central damage of the olfactory system.


Description:

Prospective monocentric descriptive study. Evaluation of COVID-19 patients with persistent loss of smell during 2 visits at 1 year intervals (V1 and V2). V1 :The following examinations will be carried out specifically for the research. - Clinical examination; - Blood sampling; - Recording of olfactory evoked potentials; - Neurological examination and neuropsychological assessment; V2 : All examinations performed at V1 will be repeated at V2. If the following examinations are not carried out during care within 3 weeks of V2, they will be carried out as part of the research during this V2 visit. - Nasal endoscopy ; - Assessment of olfactory and gustatory functions. The following explorations will be carried out: - Passing of two olfactory and gustatory scales; Olfactory and gustatory disorders will be quantified using two scales, the visual analogue scale VAS and the modified TSS; - Sniffin Stick test. In addition, MRI data from clinical care will be collected.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date November 9, 2024
Est. primary completion date November 9, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: - Adults < 55 years - History of symptomatic COVID over 1 year +/- 4 months with a positive PCR diagnosis of SARS-CoV-2 - Olfactory complaint - Able to understand simple questionnaires in French. - Subject covered by French Social Security (except for Aide Médicale d'Etat). Exclusion Criteria: - Contraindication to nasal swabbing (for morphological reasons, haemostasis disorders, taking aspirin in the 15 days prior to swabbing or anticoagulants, contraindications to the use of a local anaesthetic such as a history of allergy to local anaesthetics or any other reasons judged by the clinical investigator) - To have been placed in the intensive care unit following COVID-19. - Known previous nasal-sinus pathology. - History of psychiatric pathology according to DSM IV criteria, ischaemic, neoplastic, inflammatory, infectious or neurodegenerative (meningitis, encephalopathy, encephalitis, stroke, neurodegenerative disease) known or suspected. - History of loss of sense of smell prior to COVID infection. - Patient affiliated to the Aide Médicale d'Etat. - Person deprived of liberty by judicial or administrative decision, or subject to legal protection.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Clinical examination
The investigator will conduct a clinical examination to rule out other causes of olfactory impairment independent of COVID-19. The investigator will also collect the following information: socio-demographic data (age, sex, blood type, weight, height, etc.), history of olfaction disorder symptoms, past or current treatments received and tobacco/alcohol consumption.
Blood collection
12ml-blood sample
Olfactory evoked potentials
Olfactory evoked potentials will be recorded during olfactory tests.
Brushing of olfactory slits
collection of olfactory slits cells.
Neurological examination and neuropsychological assessment
MOCA, BREF CVLT WAIS IV, MEM III Right-side and left-side empan, Trail Making Test A and B (TMT), verbal fluency tests, PASAT, Attention Assessment Test Benton's Line Judgement, VOSP Assessment of psychological status, fatigue and screening for psychiatric comorbidities: depression & anxiety scales (HAD scale, mADRS depression scale, STAI anxiety scale), Fatigue Severity Scale.
Nasal endoscopy
Nasal endoscopy
Assessment of olfactory and taste functions
scales: VAS and TSS Sniffin Stick test

Locations

Country Name City State
France Hôpital Lariboisière Paris

Sponsors (2)

Lead Sponsor Collaborator
Institut Pasteur Hopital Lariboisière

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Measurement of olfactory responses by PEO recording and by calculating the TDI score of the Sniffin'stick tests. To characterise the evolution of the olfactory capacities of patients suffering from persistent odour disorders following SARS-CoV-2 infection over the course of a year. 24 months
Secondary Measurement of olfactory perception threshold, olfactory discrimination capacity and odour identification. Describe the olfactory performance 24 months
Secondary To characterise the persistence of SARS-CoV-2 in the olfactory epithelium. Characterisation of the presence of SARS-CoV-2 by PCR in the olfactory mucosa. 24 months
Secondary To characterise any damage to the olfactory nerve Mapping analysis of the olfactory nerve of COVID-19 patients by MRI tractography technique. 24 months
Secondary To identify the presence of inflammatory markers in patients. Measurement of cellular and inflammatory markers in the olfactory mucosa. 24 months
Secondary Detection and measurement of markers of neurological disorders in the blood. To identify the neurological damage in patients. 24 months
Secondary Measurement of patients' cognitive performance by neuropsychological assessment (standardised tests). To identify possible cognitive abnormalities in these patients with prolonged loss of smell. 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT05063214 - Muscle Evaluation of Patients Infected by the Coronavirus
Not yet recruiting NCT05013034 - Exploratory Regimen of Basiliximab for Treatment of Pulmonary Cytokine Storm in SARS-CoV-2 Hospitalized Adult Patients Phase 2
Completed NCT04998253 - Effects in Oxygenation and Hypoxic Pulmonary Vasoconstriction in ARDS Secondary to SARS-CoV2 Early Phase 1
Active, not recruiting NCT05167227 - Does a Technology Enabled Multi-disciplinary Team-based Care Model for the Management of Long COVID and Other Fatiguing Illnesses Improve Clinical Care of Patients and Represent a Sustainable Approach Within a Federally Qualified Health Center? N/A
Withdrawn NCT05393999 - SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2 Neutralising Antibodies in High-risk Populations Phase 2
Completed NCT05142553 - Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Healthy Adults Volunteers Fully Vaccinated Followed by an Extension Period to Study a Fourth Dose Administration. Phase 2
Recruiting NCT04929691 - The CircumVent Project: A CPAP/O2 Helmet Solution for Non-Invasive Ventilation Among Patients With COVID-19 N/A
Completed NCT05142514 - Safety and Immunogenicity of Recombinant Protein RBD Fusion Dimer Vaccine Against the Virus That Cause COVID-19, Known as Severe Acute Respiratoy Syndrome Coronavirus 2 (SARS-CoV-2) Phase 2
Withdrawn NCT04894682 - Safety and Long-term Effects of COVID-19 Vaccines in Patients With Pulmonary Tumor
Completed NCT04845048 - Active Pharmacovigilance Study of Adsorbed COVID-19 (Inactivated) Vaccine
Completed NCT05638178 - The Corona Study of Middle Norway
Not yet recruiting NCT05248373 - Safety, Tolerability and Immunogenicity of Gam-COVID-Vac Vaccine in a Nasal Spray Phase 1/Phase 2
Not yet recruiting NCT05074121 - NAC for Attenuation of COVID-19 Symptomatology Phase 2
Completed NCT05305573 - Assessing the Immunogenicity and Safety of a HIPRA's Candidate Booster Vaccination in Adults Fully Vaccinated With Adenovirus Vaccine Against COVID-19. Phase 2
Completed NCT05042193 - A Prospective Virtual Study to Evaluate the Longevity of IgG Antibodies in Individuals Exposed to COVID-19
Completed NCT04896866 - Efficacy and Safety of Antimicrobial Stewardship Intervention in Hospitalized COVID-19 Patients (COVASP) N/A
Completed NCT04371471 - Pandemic Triage Score in Patients With Known or Suspected Severe Acute Respiratory Syndrome (SARS) CoronaVirus (CoV) 2 Infection
Completed NCT05008562 - How COVID-19 Effects to Muscle Mass Change ın ICU?
Completed NCT04954157 - Studies to Determine Whether Oxygen Sensing is Impaired in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infected Patients N/A
Withdrawn NCT04913142 - About Oral and Gut Microbiota in Intensive Care Unit : SARS-CoV-2 (COVID-19) Infection Impact.